

LIFELINE THERAPEUTICS, INC.

Form 8-K

February 07, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): February 6, 2006  
Lifeline Therapeutics, Inc.  
(Exact name of registrant as specified in its charter)**

**Colorado**

**000-30489**

**84-1097796**

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

6400 South Fiddler s Green Circle, Suite 1970, Englewood, CO 80111

(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (720) 488-1711

6400 South Fiddler s Green Circle, Suite 1750, Englewood, CO 80111

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure**

On February 6, 2006, Lifeline Therapeutics, Inc. (the Company ) issued a press release entitled Lifeline Therapeutics, Inc. Files Amendment No. 1 to Form SB-2. The press release is attached as Exhibit 99.1 hereto.

On February 7, 2006, the Company issued a press release entitled Dr. Larry Gold Joins Lifeline Therapeutics, Inc. Scientific Advisory Board. The press release is attached as Exhibit 99.2 hereto.

**Item 9.01 Exhibits**

99.1 Press Release, dated February 6, 2006, entitled Lifeline Therapeutics, Inc. Files Amendment No. 1 to Form SB-2.

99.2 Press Release, dated February 7, 2006, entitled Dr. Larry Gold Joins Lifeline Therapeutics, Inc. Scientific Advisory Board.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 7, 2006

LIFELINE THERAPEUTICS, INC.

By: /s/ Stephen K. Onody  
Stephen K. Onody  
Chief Executive Officer

**EXHIBIT INDEX**

<u>No.</u>	<u>Description</u>
99.1	Press Release, dated February 6, 2006, entitled Lifeline Therapeutics, Inc. Files Amendment No. 1 to Form SB-2.
99.2	Press Release, dated February 7, 2006, entitled Dr. Larry Gold Joins Lifeline Therapeutics, Inc. Scientific Advisory Board.